副腎皮質がん治療の世界市場

副腎皮質がん治療の世界市場は2030年までに10億米ドルに達する見込み

2023年に7億7,500万米ドルと推定される副腎皮質がん治療の世界市場は、分析期間2023-2030年にCAGR 3.9%で成長し、2030年には10億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである化学療法は、CAGR 3.4％を記録し、分析期間終了時には2億9,730万米ドルに達すると予測されます。標的療法分野の成長率は、分析期間中CAGR 4.8％と推定されます。

米国市場は2億1,110万米ドルと推定、中国はCAGR 7.2％で成長予測

米国の副腎皮質がん治療市場は、2023年に2億1,110万米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年にかけてCAGR 7.2%で推移し、2030年には2億1,160万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.4%と2.9%と予測されています。欧州では、ドイツがCAGR 2.1%で成長すると予測されています。

世界の副腎皮質がん治療市場- 主要動向と促進要因まとめ

副腎皮質がん（ACC）は、コルチゾール、アルドステロン、アンドロゲンなどの必須ホルモンの産生を担う副腎の皮質に発生する希少かつ侵攻性のがんです。そのまれさと侵攻性の性質により、ACCは診断と治療においてしばしば重大な課題を提示します。初期症状は腹痛や体重減少など非特異的なことが多く、他の疾患と間違われることもあります。その結果、ACCは進行した段階で診断されることが多いです。ACCの主な治療は外科的切除で、腫瘍を完全に取り除くことを目的とします。手術が最も効果的なのは、がんが早期に発見され、転移がない場合です。しかし、ACCの侵攻性を考慮すると、多くの患者は進行した病変を呈し、さらなる治療アプローチが必要となります。

手術以外の治療法としては、副腎皮質がん細胞を標的とする薬剤であるミトタンのような補助療法があります。ミトタンは副腎ホルモンの産生を阻害し、がん細胞を直接攻撃することで効果を発揮するが、重大な副作用を引き起こす可能性があり、厳重な監視が必要です。手術が不可能な場合やがんが広がっている場合には、エトポシド、ドキソルビシン、シスプラチンなどの薬剤を含む化学療法レジメンが利用されます。最近の放射線療法の進歩は、転移部位や術後の残存病変を標的とする選択肢も提供しています。さらに、標的療法や免疫療法などの新しい治療法も臨床試験で検討されています。これらの新しいアプローチは、ACCと闘うために特定の遺伝子変異や免疫反応を利用することを目的としており、予後や生存率の改善に希望を与えるものです。

副腎皮質がん治療市場の成長は、画像診断や分子生物学の進歩など、早期発見や疾患の遺伝的基盤の理解を促進するいくつかの要因によって牽引されています。個別化医療の普及は、ACC患者に見られる特定の遺伝子変化に合わせた標的治療の開発につながっています。さらに、内分泌疾患に対する認識が高まり、スクリーニングプロトコールが改善され、早期診断と治療開始に寄与しています。より高度で包括的な治療を求める消費者の行動は、腫瘍学における医療費の増加と相まって、革新的な治療に対する需要を支えています。希少疾病用医薬品や希少がん研究に対する規制当局の支援も重要な役割を果たしており、製薬企業がACC療法に投資するインセンティブとなっています。これらの要因が相まって、ACC治療市場はダイナミックに拡大しており、継続的な技術革新と研究によって患者の予後を改善し、生存率を向上させることに注力しています。

調査対象企業の例（注目の43社）

• 3S Corporation
• Bristol-Myers Squibb Company
• Cayman Chemical Company
• Enterome SA
• Exelixis, Inc.
• Fresenius Kabi USA
• HRA Pharma Rare Diseases
• Integra Lifesciences Corporation
• Ipsen Pharma
• Merck & Co., Inc.
• Orphagen Pharmaceuticals
• Pfizer Inc.
• Radionetics Oncology, Inc.,
• SimSon Pharma Limited
• Tempest Therapeutics, Inc.;

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Adrenocortical Carcinoma Treatment Market to Reach US$1.0 Billion by 2030

The global market for Adrenocortical Carcinoma Treatment estimated at US$775.0 Million in the year 2023, is expected to reach US$1.0 Billion by 2030, growing at a CAGR of 3.9% over the analysis period 2023-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$297.3 Million by the end of the analysis period. Growth in the Targeted Therapy segment is estimated at 4.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$211.1 Million While China is Forecast to Grow at 7.2% CAGR

The Adrenocortical Carcinoma Treatment market in the U.S. is estimated at US$211.1 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$211.6 Million by the year 2030 trailing a CAGR of 7.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Global Adrenocortical Carcinoma Treatment Market - Key Trends and Drivers Summarized

Adrenocortical carcinoma (ACC) is a rare and aggressive cancer originating in the cortex of the adrenal gland, which is responsible for producing essential hormones such as cortisol, aldosterone, and androgens. Due to its rarity and aggressive nature, ACC often presents significant challenges in diagnosis and treatment. Early symptoms are often nonspecific, such as abdominal pain and weight loss, and can be mistaken for other conditions. As a result, ACC is frequently diagnosed at an advanced stage. The primary treatment for ACC is surgical resection, which aims to remove the tumor completely. Surgery is most effective when the cancer is detected early and has not metastasized. However, given the aggressive behavior of ACC, many patients present with advanced disease that requires additional therapeutic approaches.

Beyond surgery, the treatment landscape for ACC includes adjuvant therapies such as mitotane, a drug specifically used to target adrenocortical cancer cells. Mitotane works by inhibiting the production of adrenal hormones and directly attacking cancer cells, but it can cause significant side effects and requires close monitoring. In cases where surgery is not feasible or the cancer has spread, chemotherapy regimens including drugs like etoposide, doxorubicin, and cisplatin are utilized. Recent advancements in radiation therapy have also provided options for targeting metastatic sites or residual disease post-surgery. Furthermore, emerging treatments such as targeted therapies and immunotherapies are under investigation in clinical trials. These novel approaches aim to exploit specific genetic mutations and immune responses to combat ACC, offering hope for improved outcomes and survival rates.

The growth in the adrenocortical carcinoma treatment market is driven by several factors, including advancements in diagnostic imaging and molecular biology, which facilitate earlier detection and a better understanding of the genetic underpinnings of the disease. The increasing adoption of personalized medicine has led to the development of targeted therapies tailored to the specific genetic alterations found in ACC patients. Additionally, there is a rising awareness and improved screening protocols for endocrine disorders, contributing to earlier diagnosis and treatment initiation. Consumer behavior towards seeking more advanced and comprehensive care options, coupled with increased healthcare expenditure in oncology, supports the demand for innovative treatments. Regulatory support for orphan drugs and rare cancer research also plays a crucial role, providing incentives for pharmaceutical companies to invest in ACC therapies. These factors collectively ensure a dynamic and expanding market for ACC treatment, focused on improving patient outcomes and extending survival rates through continuous innovation and research.

Select Competitors (Total 43 Featured) -

• 3S Corporation
• Bristol-Myers Squibb Company
• Cayman Chemical Company
• Enterome SA
• Exelixis, Inc.
• Fresenius Kabi USA
• HRA Pharma Rare Diseases
• Integra Lifesciences Corporation
• Ipsen Pharma
• Merck & Co., Inc.
• Orphagen Pharmaceuticals
• Pfizer Inc.
• Radionetics Oncology, Inc.,
• SimSon Pharma Limited
• Tempest Therapeutics, Inc.;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Adrenocortical Carcinoma Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Growing Global Prevalence of Cancer Increases Demand for Effective Therapies
  • Development of New Diagnostic Methods Enhances Early Detection of Adrenocortical Carcinoma
  • Emergence of Immunotherapy in Clinical Trials as a Newer Way to Treat Adrenocortical Carcinoma
  • Increasing R&D Investment in Orphan Drug Development Expands Treatment Avenues
  • Impact of AI and Machine Learning on Cancer Treatment Predictions and Outcomes
  • Expansion of Specialty Care Centers Offering Dedicated Oncology Services Bodes Well for Market Growth
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Adrenocortical Carcinoma Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Adrenocortical Carcinoma Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Adrenocortical Carcinoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Adjuvant Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Adjuvant Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Adjuvant Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Therapy Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Therapy Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for Other Therapy Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 22: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers (ASCs) End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Ambulatory Surgery Centers (ASCs) End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 25: World 16-Year Perspective for Ambulatory Surgery Centers (ASCs) End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 28: World 16-Year Perspective for Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Cancer Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Cancer Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 31: World 16-Year Perspective for Cancer Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Adrenocortical Carcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 32: USA Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 34: USA 16-Year Perspective for Adrenocortical Carcinoma Treatment by Therapy Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 37: USA 16-Year Perspective for Adrenocortical Carcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Canada Historic Review for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 40: Canada 16-Year Perspective for Adrenocortical Carcinoma Treatment by Therapy Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 43: Canada 16-Year Perspective for Adrenocortical Carcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
• JAPAN
  • Adrenocortical Carcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 44: Japan Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Japan Historic Review for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 46: Japan 16-Year Perspective for Adrenocortical Carcinoma Treatment by Therapy Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 47: Japan Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Japan Historic Review for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 49: Japan 16-Year Perspective for Adrenocortical Carcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
• CHINA
  • Adrenocortical Carcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 50: China Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 51: China Historic Review for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 52: China 16-Year Perspective for Adrenocortical Carcinoma Treatment by Therapy Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 53: China Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 54: China Historic Review for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 55: China 16-Year Perspective for Adrenocortical Carcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
• EUROPE
  • Adrenocortical Carcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 56: Europe Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 57: Europe Historic Review for Adrenocortical Carcinoma Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 58: Europe 16-Year Perspective for Adrenocortical Carcinoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 59: Europe Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 60: Europe Historic Review for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 61: Europe 16-Year Perspective for Adrenocortical Carcinoma Treatment by Therapy Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 62: Europe Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 63: Europe Historic Review for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 64: Europe 16-Year Perspective for Adrenocortical Carcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
• FRANCE
  • Adrenocortical Carcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 65: France Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 66: France Historic Review for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 67: France 16-Year Perspective for Adrenocortical Carcinoma Treatment by Therapy Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 68: France Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 69: France Historic Review for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 70: France 16-Year Perspective for Adrenocortical Carcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
• GERMANY
  • Adrenocortical Carcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 71: Germany Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 72: Germany Historic Review for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 73: Germany 16-Year Perspective for Adrenocortical Carcinoma Treatment by Therapy Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 74: Germany Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 75: Germany Historic Review for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 76: Germany 16-Year Perspective for Adrenocortical Carcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 77: Italy Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 78: Italy Historic Review for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 79: Italy 16-Year Perspective for Adrenocortical Carcinoma Treatment by Therapy Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 80: Italy Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 81: Italy Historic Review for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 82: Italy 16-Year Perspective for Adrenocortical Carcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Adrenocortical Carcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 83: UK Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 84: UK Historic Review for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 85: UK 16-Year Perspective for Adrenocortical Carcinoma Treatment by Therapy Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 86: UK Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 87: UK Historic Review for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 88: UK 16-Year Perspective for Adrenocortical Carcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
• SPAIN
  • TABLE 89: Spain Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 90: Spain Historic Review for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 91: Spain 16-Year Perspective for Adrenocortical Carcinoma Treatment by Therapy Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 92: Spain Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Spain Historic Review for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 94: Spain 16-Year Perspective for Adrenocortical Carcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
• RUSSIA
  • TABLE 95: Russia Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Russia Historic Review for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 97: Russia 16-Year Perspective for Adrenocortical Carcinoma Treatment by Therapy Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 98: Russia Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 99: Russia Historic Review for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 100: Russia 16-Year Perspective for Adrenocortical Carcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 102: Rest of Europe Historic Review for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 103: Rest of Europe 16-Year Perspective for Adrenocortical Carcinoma Treatment by Therapy Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 105: Rest of Europe Historic Review for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 106: Rest of Europe 16-Year Perspective for Adrenocortical Carcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Adrenocortical Carcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 108: Asia-Pacific Historic Review for Adrenocortical Carcinoma Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 109: Asia-Pacific 16-Year Perspective for Adrenocortical Carcinoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 111: Asia-Pacific Historic Review for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 112: Asia-Pacific 16-Year Perspective for Adrenocortical Carcinoma Treatment by Therapy Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 114: Asia-Pacific Historic Review for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 115: Asia-Pacific 16-Year Perspective for Adrenocortical Carcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
• AUSTRALIA
  • Adrenocortical Carcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
  • TABLE 116: Australia Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 117: Australia Historic Review for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 118: Australia 16-Year Perspective for Adrenocortical Carcinoma Treatment by Therapy Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 119: Australia Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 120: Australia Historic Review for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 121: Australia 16-Year Perspective for Adrenocortical Carcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
• INDIA
  • Adrenocortical Carcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
  • TABLE 122: India Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 123: India Historic Review for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 124: India 16-Year Perspective for Adrenocortical Carcinoma Treatment by Therapy Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 125: India Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 126: India Historic Review for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 127: India 16-Year Perspective for Adrenocortical Carcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
• SOUTH KOREA
  • TABLE 128: South Korea Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 129: South Korea Historic Review for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 130: South Korea 16-Year Perspective for Adrenocortical Carcinoma Treatment by Therapy Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 131: South Korea Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 132: South Korea Historic Review for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 133: South Korea 16-Year Perspective for Adrenocortical Carcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 135: Rest of Asia-Pacific Historic Review for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Adrenocortical Carcinoma Treatment by Therapy Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 138: Rest of Asia-Pacific Historic Review for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 139: Rest of Asia-Pacific 16-Year Perspective for Adrenocortical Carcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
• LATIN AMERICA
  • Adrenocortical Carcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
  • TABLE 140: Latin America Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 141: Latin America Historic Review for Adrenocortical Carcinoma Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 142: Latin America 16-Year Perspective for Adrenocortical Carcinoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • TABLE 143: Latin America Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 144: Latin America Historic Review for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 145: Latin America 16-Year Perspective for Adrenocortical Carcinoma Treatment by Therapy Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 146: Latin America Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 147: Latin America Historic Review for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 148: Latin America 16-Year Perspective for Adrenocortical Carcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
• ARGENTINA
  • TABLE 149: Argentina Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 150: Argentina Historic Review for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 151: Argentina 16-Year Perspective for Adrenocortical Carcinoma Treatment by Therapy Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 152: Argentina Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 153: Argentina Historic Review for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 154: Argentina 16-Year Perspective for Adrenocortical Carcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
• BRAZIL
  • TABLE 155: Brazil Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 156: Brazil Historic Review for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 157: Brazil 16-Year Perspective for Adrenocortical Carcinoma Treatment by Therapy Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 158: Brazil Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 159: Brazil Historic Review for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 160: Brazil 16-Year Perspective for Adrenocortical Carcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
• MEXICO
  • TABLE 161: Mexico Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 162: Mexico Historic Review for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 163: Mexico 16-Year Perspective for Adrenocortical Carcinoma Treatment by Therapy Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 164: Mexico Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 165: Mexico Historic Review for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 166: Mexico 16-Year Perspective for Adrenocortical Carcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
• REST OF LATIN AMERICA
  • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 168: Rest of Latin America Historic Review for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 169: Rest of Latin America 16-Year Perspective for Adrenocortical Carcinoma Treatment by Therapy Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 171: Rest of Latin America Historic Review for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 172: Rest of Latin America 16-Year Perspective for Adrenocortical Carcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
• MIDDLE EAST
  • Adrenocortical Carcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
  • TABLE 173: Middle East Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 174: Middle East Historic Review for Adrenocortical Carcinoma Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 175: Middle East 16-Year Perspective for Adrenocortical Carcinoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • TABLE 176: Middle East Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 177: Middle East Historic Review for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 178: Middle East 16-Year Perspective for Adrenocortical Carcinoma Treatment by Therapy Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 179: Middle East Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 180: Middle East Historic Review for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 181: Middle East 16-Year Perspective for Adrenocortical Carcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
• IRAN
  • TABLE 182: Iran Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 183: Iran Historic Review for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 184: Iran 16-Year Perspective for Adrenocortical Carcinoma Treatment by Therapy Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 185: Iran Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 186: Iran Historic Review for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 187: Iran 16-Year Perspective for Adrenocortical Carcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
• ISRAEL
  • TABLE 188: Israel Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 189: Israel Historic Review for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 190: Israel 16-Year Perspective for Adrenocortical Carcinoma Treatment by Therapy Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 191: Israel Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 192: Israel Historic Review for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 193: Israel 16-Year Perspective for Adrenocortical Carcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
• SAUDI ARABIA
  • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 195: Saudi Arabia Historic Review for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 196: Saudi Arabia 16-Year Perspective for Adrenocortical Carcinoma Treatment by Therapy Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 198: Saudi Arabia Historic Review for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 199: Saudi Arabia 16-Year Perspective for Adrenocortical Carcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
• UNITED ARAB EMIRATES
  • TABLE 200: UAE Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 201: UAE Historic Review for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 202: UAE 16-Year Perspective for Adrenocortical Carcinoma Treatment by Therapy Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 203: UAE Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 204: UAE Historic Review for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 205: UAE 16-Year Perspective for Adrenocortical Carcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
• REST OF MIDDLE EAST
  • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 207: Rest of Middle East Historic Review for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 208: Rest of Middle East 16-Year Perspective for Adrenocortical Carcinoma Treatment by Therapy Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 210: Rest of Middle East Historic Review for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 211: Rest of Middle East 16-Year Perspective for Adrenocortical Carcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030
• AFRICA
  • Adrenocortical Carcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
  • TABLE 212: Africa Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 213: Africa Historic Review for Adrenocortical Carcinoma Treatment by Therapy Type - Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 214: Africa 16-Year Perspective for Adrenocortical Carcinoma Treatment by Therapy Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Radiation Therapy, Adjuvant Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
  • TABLE 215: Africa Recent Past, Current & Future Analysis for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 216: Africa Historic Review for Adrenocortical Carcinoma Treatment by End-Use - Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 217: Africa 16-Year Perspective for Adrenocortical Carcinoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers (ASCs) End-Use, Clinics End-Use and Cancer Research Institutes End-Use for the Years 2014, 2024 & 2030

IV. COMPETITION